Clinical Trial Update: A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors [Phase 2]

View source ↗

Summary

Clinical trial update reports completion of a Phase 2 study evaluating atrasentan to reduce albuminuria in patients with type 2 diabetes and diabetic nephropath…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetic Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Status: COMPLETED